Trials / Withdrawn
WithdrawnNCT03070314
Echinaforce Junior Bioavailability Trial
Bioavailability of an Echinacea Product (Echinaforce® Junior) in Children With a Common Cold, Aged 4-12 Years After Intake of a Daily Dosage
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- A. Vogel AG · Industry
- Sex
- All
- Age
- 4 Years – 12 Years
- Healthy volunteers
- Not accepted
Summary
In this bioavailability trial should be shown that the one of the main active constituent in alcoholic echinacea extracts, the alkylamide dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamide (short: tetraen) is bioavailable in children of different age groups after intake of 5 Echinaforce junior tablets.
Detailed description
In this bioavailability trial should be shown that the one of the main active constituent in alcoholic echinacea extracts, the alkylamide dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamide (short: tetraen) is bioavailable in children of different age groups after intake of 5 Echinaforce junior tablets. Six capillary blood draws are taken at the following time points: Start (0), after 15, 30, 60, 90, 270 minutes and thereafter the bioavailability is measured and calculated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Echinaforce junior | Echinacea Purpurea Extract Pill, sweetened and with orange flavour |
Timeline
- Start date
- 2017-02-20
- Primary completion
- 2018-06-30
- Completion
- 2018-06-30
- First posted
- 2017-03-03
- Last updated
- 2018-07-18
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT03070314. Inclusion in this directory is not an endorsement.